Biocon And Mylan's Fulphila And Insulin Plans On Track
FDA Expected To Inspect Malaysia Insulins Facility In February
Biocon and Mylan press ahead with plans to broaden patient access in the US to biosimilar pegfilgrastim and are enthused with the initial uptake for their trastuzumab biosimilar ahead of more upcoming competition. A mid-2020 US launch for partnered insulin glargine is also on course.
